This SP always behaves oddly on positive news - make of that what you will.
I think fundamentals and financials are more important in truly valuing a share than recent buying patterns. With a biotech like this IP, peer reviewed publications, clinical guidelines and regulatory approvals are also crucial.
It would seem contradictory for China to rank UCM priority on their technology list which includes preference for govt contracts and then backtrack on this approval at the last hour.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.759M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500000 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 46000 | 1 |
View Market Depth
| Last trade - 16.21pm 27/06/2025 (20 minute delay) ? |
| UCM (ASX) Chart |
Day chart unavailable